Search

Your search keyword '"Mateos, María V."' showing total 14 results
Start Over Author "Mateos, María V."
14 results on '"Mateos, María V."'

1. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Author

Grosicki, Sebastian, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kriachok, Iryrna, Gavriatopoulou, Maria, Pylypenko, Halyna, Auner, Holger W, Leleu, Xavier, Doronin, Vadim, Usenko, Ganna, Bahlis, Nizar J, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan K, Sinha, Dinesh K, Venner, Christopher P, Garg, Mamta, Gironella, Mercedes, Jurczyszyn, Artur, Robak, Pawel, Galli, Monica, Wallington-Beddoe, Craig, Radinoff, Atanas, Salogub, Galina, Stevens, Don A, Basu, Supratik, Liberati, Anna M, Quach, Hang, Goranova-Marinova, Vesselina S, Bila, Jelena, Katodritou, Eirini, Oliynyk, Hanna, Korenkova, Sybiryna, Kumar, Jeevan, Jagannath, Sundar, Moreau, Phillipe, Levy, Moshe, White, Darrell, Gatt, Moshe E, Facon, Thierry, Mateos, Maria V, Cavo, Michele, Reece, Donna, Anderson, Larry D, Jr, Saint-Martin, Jean-Richard, Jeha, Jacqueline, Joshi, Anita A, Chai, Yi, Li, Lingling, Peddagali, Vishnuvardhan, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Dimopoulos, Meletios A, Richardson, Paul G, and Delimpasi, Sosana

Published
2020
Full Text
View/download PDF

2. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

Author

Jiménez, Cristina, Jara-Acevedo, María, Corchete, Luis A., Castillo, David, Ordóñez, Gonzalo R., Sarasquete, María E., Puig, Noemí, Martínez-López, Joaquín, Prieto-Conde, María I., García-Álvarez, María, Chillón, María C., Balanzategui, Ana, Alcoceba, Miguel, Oriol, Albert, Rosiñol, Laura, Palomera, Luis, Teruel, Ana I., Lahuerta, Juan J., Bladé, Joan, Mateos, María V., Orfão, Alberto, San Miguel, Jesús F., González, Marcos, Gutiérrez, Norma C., and García-Sanz, Ramón

Published
2017
Full Text
View/download PDF

3. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

Author

Palumbo, Antonio, Bringhen, Sara, Ludwig, Heinz, Dimopoulos, Meletios A., Bladé, Joan, Mateos, Maria V., Rosiñol, Laura, Boccadoro, Mario, Cavo, Michele, Lokhorst, Henk, Zweegman, Sonja, Terpos, Evangelos, Davies, Faith, Driessen, Christoph, Gimsing, Peter, Gramatzki, Martin, Hàjek, Roman, Johnsen, Hans E., Leal Da Costa, Fernando, Sezer, Orhan, Spencer, Andrew, Beksac, Meral, Morgan, Gareth, Einsele, Hermann, San Miguel, Jesus F., and Sonneveld, Pieter

Published
2011
Full Text
View/download PDF

4. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

Author

Paiva, Bruno, Vidriales, Maria-Belén, Cerveró, Jorge, Mateo, Gema, Pérez, Jose J., Montalbán, Maria A., Sureda, Anna, Montejano, Laura, Gutiérrez, Norma C., de Coca, Alfonso García, de las Heras, Natalia, Mateos, Maria V., López-Berges, Maria C., García-Boyero, Raimundo, Galende, Josefina, Hernández, Jose, Palomera, Luis, Carrera, Dolores, Martínez, Rafael, de la Rubia, Javier, Martín, Alejandro, Bladé, Joan, Lahuerta, Juan J., Orfao, Alberto, and San Miguel, Jesús F.

Published
2008
Full Text
View/download PDF

5. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

Author

Santamaría, Carlos, Chillón, María C., García-Sanz, Ramón, Pérez, Cristina, Caballero, María D., Mateos, María V., Ramos, Fernando, de Coca, Alfonso García, Alonso, José M., Giraldo, Pilar, Bernal, Teresa, Queizán, José A., Rodríguez, Juan N., Puig, Noemí, Balanzategui, Ana, Sarasquete, María E., Alcoceba, Miguel, Díaz-Mediavilla, Joaquín, San Miguel, Jesús, and González, Marcos

Published
2010
Full Text
View/download PDF

7. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation

Author

Moscardó, Federico, Urbano-Ispizua, Álvaro, Sanz, Guillermo F, Brunet, Salut, Caballero, Dolores, Vallejo, Carlos, Solano, Carlos, Pimentel, Pedro, Pérez de Oteyza, Jaime, Ferrá, Christelle, Dı́ez-Martı́n, José L, Zuazu, Javier, Espigado, Ildefonso, Campilho, Fernando, Arbona, Cristina, Moraleda, José M, Mateos, Marı́a V, Sierra, Jordi, Talarn, Carmen, and Sanz, Miguel A

Published
2003
Full Text
View/download PDF

8. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial

Author

García-Sanz, Ramón, Albert, Oriol, Moreno, María J., Rubia, Javier de la, Payer, Angel R., Hernández, Miguel T., Palomera, Luis, Teruel, Ana I., Blanchard, María J., Gironella, Mercedes, Ribas, Paz, Bargay, Joan, Abella Monreal, Eugenia, Granell, Miquel, Ocio, Enrique M., Ribera, Josep Maria, San Miguel, Jesús F., Mateos, María V., Spanish Myeloma Group (GEM/PETHEMA)., Novartis, Asociación Española Contra el Cáncer, European Commission, Red Temática de Investigación Cooperativa en Cáncer (España), Ministerio de Economía y Competitividad (España), and Instituto de Salud Carlos III

Subjects
Adult, medicine.medical_specialty, Bone disease, Anemia, InformationSystems_INFORMATIONSTORAGEANDRETRIEVAL, Asymptomatic, Gastroenterology, Zoledronic Acid, Disease-Free Survival, Internal medicine, medicine, Humans, Survival rate, Multiple myeloma, Aged, Treated group, Diphosphonates, business.industry, Mieloma múltiple, Imidazoles, Articles, Hematology, Middle Aged, medicine.disease, Surgery, Survival Rate, Zoledronic acid, Biochemical relapse, medicine.symptom, Bone Diseases, business, Multiple Myeloma, medicine.drug
Abstract

This is an open-access paper.-- This trial was registered in the ClinicalTrials.gov database with code NCT01087008., Spanish Myeloma Group (GEM/PETHEMA): et al., This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 versus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was different for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunction (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P, This work was supported by an unrestricted grant from Novartis Farmaceutica S.A., Barcelona, Spain and sponsored by GEM/PETHEMA. Part of the work was also done thanks to grants PS09/01450 and PI12/02311 from the Spanish “Instituto de Salud Carlos III (ISCIII)” and Fondo Europeo de Desarrollo Regional (FEDER), the Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund (ERDF) “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010), the grant RD12/0036/0069 from “Red Temática de Investigación Cooperativa en Cáncer (RTICC), and grant GCB-120981SAN from the “Asociación Española Contra el Cáncer (AECC)”.

Published
2015

9. Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

Author

Spicka, Ivan, Ocio, Enrique M., Oakervee, Heather E., Greil, Richard, Banh, Raymond H., Catley, Laurence, Huang, Shang-Yi, D'Rozario, James M., Dimopoulos, Meletios A., Rodríguez, José, Martinez, Sara, Extremera, Sonia, Alfaro, Vicente, Carella, Angelo Michele, Meuleman, Nathalie, Hájek, Roman, Symeonidis, Argiris, Min, Chang-Ki, Cannell, Paul, Ludwig, Heinz, Sonneveld, Pieter, and Mateos, Maria V.

Published
2017
Full Text
View/download PDF

11. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

Author

Santamaría, Carlos, primary, Chillón, María C., additional, García-Sanz, Ramón, additional, Pérez, Cristina, additional, Caballero, María D., additional, Mateos, María V., additional, Ramos, Fernando, additional, de Coca, Alfonso García, additional, Alonso, José M., additional, Giraldo, Pilar, additional, Bernal, Teresa, additional, Queizán, José A., additional, Rodríguez, Juan N., additional, Puig, Noemí, additional, Balanzategui, Ana, additional, Sarasquete, María E., additional, Alcoceba, Miguel, additional, Díaz-Mediavilla, Joaquín, additional, San Miguel, Jesús, additional, and González, Marcos, additional

Published
2009
Full Text
View/download PDF

12. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation

Author

Moscardó, Federico, Urbano-Ispizua, Álvaro, Sanz, Guillermo F., Brunet, Salut, Caballero, Dolores, Vallejo, Carlos, Solano, Carlos, Pimentel, Pedro, Pérez de Oteyza, Jaime, Ferrá, Christelle, Díez-Martín, José L., Zuazu, Javier, Espigado, Ildefonso, Campilho, Fernando, Arbona, Cristina, Moraleda, José M., Mateos, María V., Sierra, Jordi, Talarn, Carmen, and Sanz, Miguel A.

Subjects
*T cells, *LIVER diseases
Abstract

Objective. T-cell depletion (TCD), primarily developed to prevent graft-vs-host disease (GVHD), might reduce early liver dysfunction after allogeneic hematopoietic stem cell transplantation. However, no comparative studies have been performed to investigate this. We analyzed the influence of selection for CD34+ cells on the incidence and severity of hepatic veno-occlusive disease (VOD).Patients and Methods. Five hundred and one patients who underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical siblings were included in the present study. Two hundred and ninety patients (59%) were grafted with CD34+ positively selected grafts and 211 (41%) with nonmanipulated grafts. Their mean age was 38 years (range 17–63). All patients had hematological malignancies and 96% were conditioned with combinations either of cyclophosphamide plus total-body irradiation or of cyclophosphamide plus busulphan. Most of the patients received GVHD prophylaxis with methotrexate (MTX) or cyclosporin A.Results. Fifty-two patients (10.4%) developed VOD. VOD was more frequent in patients receiving nonmanipulated grafts (16.1% vs 6.2%; p<0.0009), in those with a Karnofsky score less than 90 (17.5% vs 7.8%; p = 0.001), and with the use of MTX for GVHD prophylaxis (14.8% vs 7%; p = 0.005). In multivariate analyses, only CD34+ positive selection (p = 0.0007) and Karnofsky score (p = 0.004) emerged as independent risk factors for VOD. The same effect was observed in the subset of patients with severe VOD.Conclusion. These findings show that CD34+ selection not only decreases the incidence of GVHD but also prevents VOD after HLA-identical sibling PBSCT. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

13. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.

Author

García-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernández MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abellá E, Granell M, Ocio EM, Ribera JM, San Miguel JF, and Mateos MV

Subjects
Adult, Aged, Bone Diseases pathology, Disease-Free Survival, Humans, Middle Aged, Multiple Myeloma pathology, Survival Rate, Zoledronic Acid, Bone Diseases drug therapy, Bone Diseases mortality, Diphosphonates administration & dosage, Imidazoles administration & dosage, Multiple Myeloma drug therapy, Multiple Myeloma mortality
Abstract

This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 versus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was different for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunction (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P<0.001). In summary, zoledronic acid monotherapy does not show an antitumor effect on biochemical relapses in multiple myeloma, but does reduce the risk of progression with symptomatic bone disease and skeletal complications. This trial was registered in the ClinicalTrials.gov database with code NCT01087008., (Copyright© Ferrata Storti Foundation.)

Published
2015
Full Text
View/download PDF

14. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study.

Author

Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP, Arranz R, Terol MJ, Sierra J, and San Miguel JF

Subjects
Aged, Aged, 80 and over, Anemia chemically induced, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Drug Eruptions etiology, Drug Eruptions prevention & control, Female, Granulocyte Colony-Stimulating Factor therapeutic use, Humans, Lymphoma, Large B-Cell, Diffuse mortality, Male, Nausea chemically induced, Nausea drug therapy, Neutropenia chemically induced, Neutropenia prevention & control, Prospective Studies, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy
Abstract

Background and Objectives: Anthracycline-based combination chemotherapy regimens are the standard therapy for patients with diffuse large B-cell lymphoma (DLBCL), but such regimens may be poorly tolerated in elderly patients., Design and Methods: In a prospective phase II study we analyzed the feasibility of a regimen (CCOP) that includes pegylated liposomal doxorubicin (Caelyx ) plus vincristine, cyclophosphamide and prednisone in patients with DLBCL above the age of 60 years., Results: Thirty-three patients, with a median age of 74 years, were enrolled in the study. The overall response rate was 64% (49% complete remissions and 15% partial remissions). The estimated one-year overall and event-free survivals were 55% (95% CI, 38-72) and 45% (95%CI, 28-62), respectively. The only relevant toxicity was neutropenia, which reached grades 3-4 in 21 cases (64%)., Interpretation and Conclusions: These results suggest that CCOP appears to be an acceptable alternative for elderly patients with DLBCL, and randomized trials against a conventional doxorubicin-containing regimen are justified.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results